| 基因多态性与新型口服抗凝药个体化用药概述 |
| |
| 引用本文： | 张君 蔡卫民. 基因多态性与新型口服抗凝药个体化用药概述[J]. 中国药师, 2019, 0(12): 2262-2266 |
| |
| 作者姓名： | 张君 蔡卫民 |
| |
| 作者单位： | 复旦大学药学院临床药学与药事管理教研室 上海 201203 |
| |
| 摘 要： | 摘 要新型口服抗凝药(NOACs)由于治疗窗宽、无需常规凝血监测等优势逐渐被广泛使用。近年来，NOACs的药物反应出现个体差异，有报道发现，遗传变异是导致NOACs个体间差异的重要因素，因此研究基因多态性对NOACs药物反应的影响十分必要。通过综述近年来的相关研究探讨基因多态性对新型口服抗凝药的药动学和药效学的影响，指导NOACs个体化用药，提高疗效和安全性，减少不良事件的发生。
|
| 关 键 词： | 新型口服抗凝药；达比加群酯；利伐沙班；阿哌沙班；艾多沙班；基因多态性；个体化用药 |
Summary of Genetic Polymorphism and Individualized Medication of New Oral Anticoagulants |
| |
| Zhang Jun,Cai Weimin. Summary of Genetic Polymorphism and Individualized Medication of New Oral Anticoagulants[J]. China Pharmacist, 2019, 0(12): 2262-2266 |
| |
| Authors: | Zhang Jun Cai Weimin |
| |
| Affiliation: | Department of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai 201203, China |
| |
| Abstract: | ABSTRACT New oral anticoagulants(NOACs) are gradually widely used due to their advantages such as the wide treatment window and no need for routine coagulation monitoring.In recent years, there have been individual varieties in the drug responses of NOACs. It has been reported that genetic variation is an important factor leading to the differences among individuals treated with NOACs. Therefore, it is necessary to study the effect of gene polymorphism on the drug responses of NOACs. This review aimed to investigate the effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of novel oral anticoagulants to guide the individualized medication of NOACs, improve efficacy and safety, and reduce adverse events. |
| |
| Keywords: | Novel oral anticoagulant Dabigatran etexilate Rivaroxaban Apixaban Edoxaban Gene polymorphism Individualized medication |
|
| 点击此处可从《中国药师》浏览原始摘要信息 |
|
点击此处可从《中国药师》下载全文 |
